期刊
MULTIPLE SCLEROSIS JOURNAL
卷 19, 期 9, 页码 1226-1229出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458513481010
关键词
PML; IRIS; multiple sclerosis; natalizumab
资金
- Biogen Idec
- Merck-Serono
- Sanofi-Aventis
- Genzyme
- Solvay Pharma
- Danish Multiple Sclerosis Society
- Novartis
- Sanofi Aventis
- Bayer Schering
- Merck Serono
- Genmab
- Teva
- GSK
- Baxter
- BioMS
- RoFAR
- Roche
- Danish Medical Research Council
- European Union
We report the case of a woman with natalizumab-treated multiple sclerosis (MS) and clinically silent progressive multifocal leukoencephalopathy (PML) with an unusually long preclinical phase, followed by acute symptoms due to development of immune reconstitution inflammatory syndrome (IRIS). Furthermore, the course of the IRIS was prolonged and continued to progress even five months after natalizumab treatment was ceased. This case shows that PML and IRIS can have a considerably variable course in natalizumab-treated MS patients and underlines the need for PML screening in JC virus antibody-positive patients in order to detect clinically silent cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据